Richard Harris

Award-winning journalist Richard Harris has reported on a wide range of topics in science, medicine and the environment since he joined NPR in 1986. In early 2014, his focus shifted from an emphasis on climate change and the environment to biomedical research.

Harris has traveled to all seven continents for NPR. His reports have originated from Timbuktu, the South Pole, the Galapagos Islands, Beijing during the SARS epidemic, the center of Greenland, the Amazon rain forest, the foot of Mt. Kilimanjaro (for a story about tuberculosis), and Japan to cover the nuclear aftermath of the 2011 tsunami.
In 2010, Harris' reporting revealed that the blown-out BP oil well in the Gulf of Mexico was spewing out far more oil than asserted in the official estimates. That revelation led the federal government to make a more realistic assessment of the extent of the spill.

Harris covered climate change for decades. He reported from the United Nations climate negotiations, starting with the Earth Summit in Rio de Janeiro in 1992, and including Kyoto in 1997 and Copenhagen in 2009. Harris was a major contributor to NPR's award-winning 2007-2008 "Climate Connections" series.

Over the course of his career, Harris has been the recipient of many prestigious awards. Those include the American Geophysical Union's 2013 Presidential Citation for Science and Society. He shared the 2009 National Academy of Sciences Communication Award and was a finalist again in 2011. In 2002, Harris was elected an honorary member of Sigma Xi, the scientific research society. Harris shared a 1995 Peabody Award for investigative reporting on NPR about the tobacco industry. Since 1988, the American Association for the Advancement of Science has honored Harris three times with its science journalism award.

Before joining NPR, Harris was a science writer for the San Francisco Examiner. From 1981 to 1983, Harris was a staff writer at The Tri-Valley Herald in Livermore, California, covering science, technology, and health issues related to the nuclear weapons lab in Livermore. He started his career as an AAAS Mass Media Science Fellow at the now-defunct Washington (DC) Star.

Harris is co-founder of the Washington, D.C., Area Science Writers Association, and is past president of the National Association of Science Writers. He serves on the board of the Council for the Advancement of Science Writing.

A California native, Harris returned to the University of California-Santa Cruz in 2012, to give a commencement address at Crown College, where he had given a valedictory address at his own graduation. He earned a bachelor's degree at the school in biology, with highest honors.

There's a lesson about one of the testosterone studies released this week that has nothing to do with testosterone: The study on how testosterone affects anemia was designed with an ethical lapse that nobody noticed until the study was complete.

If you think your hearing is just fine, think again. A federal study finds that about a quarter of people between the ages of 20 and 69 who think their hearing is good or excellent are in fact showing signs of hearing loss.

Hearing loss is often chalked up to noisy work environments or to aging. To be sure, those are major reasons that people's hearing becomes less acute. The Centers for Disease Control and Prevention's latest survey on hearing finds that 24 percent of hearing loss is due to loud workplaces.

A widely used blood test to measure blood-sugar trends can give imprecise results, depending on a person's race and other factors. This test means diabetes can sometimes be misdiagnosed or managed poorly.

Doctors have been cautioned before that results from the A1C test don't have pinpoint accuracy. A study published Tuesday underscores that shortcoming as it applies to people who carry the sickle cell trait.

When scientists first read out the human genome 15 years ago, there were high hopes that we'd soon understand how traits like height are inherited. It hasn't been easy. A huge effort to find height-related genes so far only explains a fraction of this trait.

Now scientists say they've made some more headway. And the effort is not just useful for understanding how genes determine height, but how they're involved in driving many other human traits.

Screening for lung cancer using low-dose CT scans can save lives, but at a cost: Tests frequently produce anxiety-producing false alarms and prompt unnecessary procedures.

A study from the Veterans Health Administration lays out the considerable effort required by both patients and doctors to undertake screening.

"I have heard people say 'what's the big deal, it's just a CT,' " says Dr. Linda Kinsinger, who ran the study at the VA. "But I think what we tried to show is it's a lot more than just a CT."

The first results from a major project to measure the reliability of cancer research have highlighted a big problem: Labs trying to repeat published experiments often can't.

That's not to say that the original studies are wrong. But the results of a review published Thursday, in the open-access journal eLife, are a sobering reminder that science often fails at one of its most basic requirements — an experiment in one lab ought to be reproducible in another one.

Chances are your doctor has stopped taking notes with pen and paper and moved to computer records. That is supposed to help coordinate your care.

Increasingly, researchers are also exploring these computerized records for medical studies and gleaning facts that help individual patients get better care.

A Canadian doctor who is opposed to a widely used drug for morning sickness has fired another volley.

Writing in the journal PLOS ONE, Dr. Navindra Persaud in the department of family and community medicine at St. Michael's Hospital in Toronto, notes that an unpublished study that supported use of the drug, conducted in the 1970s, is seriously flawed.

Studies of fish oil and health are like studies about coffee — there's plenty of contradictory information out there.

With that in mind, here's the latest turn: A Danish study finds that women who took fish oil supplements during pregnancy reduced the risk of asthma in their children.

The federal government will pay more than $100,000 to give someone a kidney transplant, but after three years, the government will often stop paying for the drugs needed to keep that transplanted kidney alive.

Constance Creasey is one of the thousands of people who find themselves caught up by this peculiar feature of the federal kidney program.

There's a bump in the number of cases of the mumps this year in the United States.

This highly infectious disease is much less hazardous than it was decades ago, but health officials are still reacting strongly to several big outbreaks.

Most years, health officials report a few hundred cases of mumps, but this year the total has topped 4,000. Most are clustered in Iowa, Illinois and, worst of all, Arkansas, which has more than 2,200 cases.

Two widely used tests to analyze the genetics of tumors often don't come to the same conclusions, according to head-to-head analyses.

Authors of two recent studies comparing these tests say doctors need to be careful not to assume that these tests are providing a complete picture of a tumor's genetic variants, when using them to select treatments for cancer patients.

The high-stakes fight over who invented a technology that could revolutionize medicine and agriculture heads to a courtroom Tuesday.

A gene-editing technology called CRISPR-cas9 could be worth billions of dollars. But it's not clear who owns the idea.

U.S. patent judges will hear oral arguments to help untangle this issue, which has far more at stake than your garden-variety patent dispute.

Updated Dec. 1, 9:05 a.m.: The House of Representatives voted overwhelmingly on Wednesday to approve the 21st Century Cures Act, a sprawling bill to fund medical research and revamp how drugs and medical devices are approved by the Food and Drug Administration.

Biomedical research is going big-time: Megaprojects that collect vast stores of data are proliferating rapidly. But scientists' ability to make sense of all that information isn't keeping up.

This conundrum took center stage at a meeting of patient advocates, called Partnering For Cures, in New York City on Nov. 15.

On the one hand, there's an embarrassment of riches, as billions of dollars are spent on these megaprojects.

Pages